The FDA's Pharmacy Compounding Advisory Committee is scheduled to review seven of them for 503A eligibility at its July 23-24, 2026 meeting
METHOD DETAILS Sample preparation FOXO4 FHD (95-195) was subcloned into the pET His6 Tobacco Etch Virus (TEV) LIC cloning vector (2B-T, obtained from Scott Gradia, Addgene Plasmid #29666) and transformed into BL21 (DE3) cells
What We Dont Yet Know Responsible disclosure requires acknowledging gaps in knowledge: Long-term effects of continuous use over months or years in humans Potential interactions with medications or other supplements Effects in specific populations (pregnant women, children, elderly, people with certain medical conditions) Optimal dosing protocols for different applications Comparative effectiveness of different administration routes Anyone considering BPC 157 should approach it as an experimental compound, ideally under guidance from a knowledgeable practitioner, and should monitor their response carefully
Injury recovery Investigated in animal studies on recovery from soft-tissue injury, including tendon, ligament, and muscle models